César Serrano García

Physician-scientist · #sarcoma #GIST @VHIO | External Group Leader @IRBBarcelona | #SanidadPública | #SinCienciaNoHayFuturo | @MyEsmo Faculty. Tweets are my own

[César Serrano García @DrCeSarcoma]

🤩 Ha sido todo un honor recibir la beca CRIS de Excelencia dotada con 1.25M€ para diseccionar a un nivel sin precedentes los mecanismos moleculares de los #Sarcomas #GIST - y poder avanzar en el tratamiento de nuestros pacientes 🧬💊

🙏🏼 Muchas gracias a la #CRIScontraelcáncer

[CRIS Contra el Cáncer @criscancer]

🔴 Para el Dr. @DrCeSarcoma del @VHIO de Barcelona por el Proyecto CRIS de Sarcomas Gastrointestinales. 

➡️ Entrega el Dr. Kevin Harrington, jefe del servicio de Radioterapia e Imagen del @CTI_ICR. 

#CRIScontraelcáncer #OtraOportunidad #DíaCienciaCRIS24

[Cancer Discovery @CD_AACR]

Now online: A Foundation Model of Cancer Genotype Enables Precise Predictions of Therapeutic Response https://t.co/s4EqsGHHcH

[Michael Alexanian @m_alexanian]

Excited to share our new review in @CellCellPress. We propose fibrosis is a reversible state encoded in chromatin circuits shaped by immune-stromal crosstalk, and that rewiring this logic may offer durable therapeutic paths. @GladstoneInst

https://t.co/PseOOQY93h

[Cancer Cell @Cancer_Cell]

Online Now: Tumor immune microenvironment remodeling predicts response to checkpoint inhibitor therapy https://t.co/UJHL5NGaqj

[GEIS @GrupoGeis]

Taller de Cirugía GEIS | 17 de septiembre · Barcelona
Una jornada dirigida a cirujanos centrada en las novedades en GIST y los avances en el manejo de los sarcomas retroperitoneales, con presentación y discusión de casos clínicos.

🎟️Inscripción gratuita: https://t.co/pBbbgCcLAU

[Nieves Martinez Lago MD PhD @DraMartinezLago]

🦴 RMS staging | FDG-PET vs bone marrow biopsy

👥 301 FDG-avid RMS
🎯 PET sensitivity 98%
✅ BM metastasis missed by PET: 1/301

💡 PET-negative marrow may allow omission of BM aspirate/biopsy.
⚠️ PET-positive lesions → consider MRI/biopsy

🔗 https://t.co/Cfp9nYYGCZ

@OncoAlert

[César Serrano García @DrCeSarcoma]

@DraMartinezLago @ASCO @myESMO @ESMO_Open @GrupoGeis @GrupoTTD + high need to refine current risk criteria incorporating molecular (KIT/PDGFRA) data

[César Serrano García @DrCeSarcoma]

@MachadoIsidrin @DraMartinezLago Thanks Isidro!

[César Serrano García @DrCeSarcoma]

@patxiqueipo @DraMartinezLago Yes, indeed. Although we use this broadly accepted term (related to the technology) to refer to its use in sarcoma diagnostics and therapeutics.

More details here 👇🏼

https://t.co/4QpSemiwa2

[Nieves Martinez Lago MD PhD @DraMartinezLago]

🧬 NGS in Sarcoma | Reply

⚠️ Universal NGS ≠ universal benefit
📉 Therapeutic gain: <1%
🏥 Expert-center care: 22% lower risk of death
🧪 NGS ≠ expert pathology

💡 Understand the disease before sequencing it.

🔗 https://t.co/x07CvZklX8

@DrCeSarcoma

[César Serrano García @DrCeSarcoma]

@DraMartinezLago Gracias 🤩

[César Serrano García @DrCeSarcoma]

@cateterdoblej ¡Excelente! Enhorabuena. Has sacado un 10 😉

[César Serrano García @DrCeSarcoma]

@EricTopol Always surprised to see the increasing amount of studies trying to demonstrate how good it is doing the less exercise possibly. It sounds like a good joke.

[Vall d’Hebron Institute of Oncology (VHIO) @VHIO]

El @DrCeSarcoma combina asistencia e investigación para dar voz a las necesidades reales de los pacientes.

💙 Con el apoyo de @ContraCancerEs, su equipo ha logrado avances pioneros en sarcomas raros como la biopsia líquida en tumores #GIST y nuevos ensayos clínicos. 

👉 https://t.co/dpCLiE4OfA

[César Serrano García @DrCeSarcoma]

@GinaDAmatoMD1 @ASCO @SylvesterCancer @breelynwilkyMD @JTrentMDPhD Congrats Gina!!! 🙌🏼

[Nature Cancer @NatureCancer]

💫Online today
The Review on intratumor heterogeneity by @Jonathancmwan, @NickyMcGranahan and @CharlesSwanton

🔗https://t.co/i5ryGR2lej

Check out the rest of the Series on Tumor Heterogeneity and Plasticity here: https://t.co/kJQO5ZYuOC

[César Serrano García @DrCeSarcoma]

🧬💊Barcelona + world-class cancer research + European fellowship

Our sarcoma lab @VHIO is recruiting a #postdoc to decode tumor evolution through the lens of chromosome instability & DNA repair — from bench to clinic #TranslationalResearch

GROUP➡️https://t.co/4ud5b46zdS

[César Serrano García @DrCeSarcoma]

@ACDPatrimonio Todo es que @UNESCO_es hable con @aytoSalamanca

[Mehdi Layeghifard @mlayeghi]

Our paper out today in @Nature:
How does prior therapy shape childhood cancer at the genomic level? 🧬

https://t.co/obm6ohm1nC
https://t.co/N1KHdpD5Y9

#Nature #CancerGenomics #MutationalSignatures #PrecisionMedicine #PediatricCancer #Resistance

[César Serrano García @DrCeSarcoma]

@ACDPatrimonio @salamancartehis ¿En dónde está?

[Elizabeth McKenna @ElizSMcKenna]

Now in @CD_AACR: 2 studies showing that CDK8 inhibitors act by trapping Mediator on chromatin & that cancers w/driver oncogenes acting as dosage-sensitive transcription factors (e.g. aRMS, Ewing sarcoma) are vulnerable to impairment of transcriptional regulatory complex dynamics: